Traders should monitor Dr. Reddy's for potential revenue upside from the 180-day exclusivity period, but note that this is a single-strength launch in a competitive generic space. Watch for any subsequent first-to-file exclusivity on other strengths or additional generic oncology launches that could compound the impact.
RDY drugs
RDY drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Jun 15 $13.33entry
- T+1 · 5mo ago −0.23%α +0.37% · $13.30
- T+5 · 5mo ago +4.35%α +5.73% · $13.91
- T+20 · 4mo ago −3.08%α −2.33% · $12.92
- T+60 · due 2mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's announced the first-to-market launch of Bosutinib Tablets 400mg (generic Bosulif) in the U.S., a tyrosine kinase inhibitor for oncology. The product was a first-to-file and qualifies for 180-day generic exclusivity for this strength. The Bosulif brand had U.S. sales of ~$253.8M over the latest 12 months ended April 2026. This is a positive, event-driven catalyst that expands Dr. Reddy's oncology portfolio, limited to a single strength and a finite exclusivity window.
Key Facts
- First-to-market launch of Bosutinib Tablets 400mg, generic equivalent of Bosulif, in the United States on June 13, 2026.
- Product is a first-to-file, eligible for 180-day generic exclusivity for this strength.
- Brand Bosulif (400mg) had U.S. sales of approximately $253.8 million for the latest 12 months ended April 2026.
- Dr. Reddy's holds exclusive marketing rights; MSN Laboratories is the development and manufacturing partner.
- Launch expands Dr. Reddy's oncology portfolio in the U.S. market.
Financial Impact
U.S. brand sales of ~$253.8M (LTM) for the 400mg strength, but generic revenue will be a fraction of that and subject to competition after 180-day exclusivity.
Risk Factors
- Generic pricing erosion and competition from other manufacturers after the 180-day exclusivity period
- Product launch delays or supply disruptions from partner MSN Laboratories
- Litigation risk from branded manufacturer (Wyeth/Pfizer) regarding patent validity or exclusivity scope
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000418 |
| Document: 0001575872-26-000418-index.html | 0001575872-26-000418 |
| Document: 0001575872-26-000418.txt | 0001575872-26-000418 |
Track record
73 reports on RDY
6 of 11 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 6 of 11 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers